Summit Therapeutics (SMMT) Assets Average (2020 - 2026)

Summit Therapeutics has reported Assets Average for 7 years, with the latest figure at $699.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 70.74% year-over-year to $699.5 million; the trailing twelve-month figure through Mar 2026 stood at $699.5 million (up 70.74% YoY), and the FY2025 full-year result was $593.4 million, up 85.86% from the prior year.
• Assets Average for Q1 2026 stood at $699.5 million, up from $506.5 million in the prior quarter.
• The five-year high for Assets Average was $699.5 million in Q1 2026, with the low at $106.1 million in Q2 2022.
• Historically, Assets Average has averaged $323.8 million across 5 years, with a median of $292.9 million in 2025.
• Annual changes were most pronounced in 2023 — Assets Average surged 299.86% — and 2024, when it tumbled 58.68%.
• Summit Therapeutics' Assets Average stood at $409.7 million in 2022, then plunged by 48.58% to $210.7 million in 2023, then jumped by 122.68% to $469.2 million in 2024, then advanced by 7.94% to $506.5 million in 2025, then soared by 38.12% to $699.5 million in 2026.
• The last three Assets Average figures came in at $699.5 million (Q1 2026), $506.5 million (Q4 2025), and $292.9 million (Q3 2025), per Business Quant data.